Online inquiry

IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2074MR)

This product GTTS-WQ2074MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets Canlupfam PDCD1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001314097.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 486213
UniProt ID A0A090BAM7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2074MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6547MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ4580MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ1731MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ADC-1013
GTTS-WQ12381MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ14716MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ1489MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ7208MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ4885MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BYM338
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW